Tissue microarrays and quantitative tissue-based image analysis as a tool for oncology biomarker and diagnostic development

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 6, 2012, Pages 569-583

  Dolled Filhart, Marisa P ^a   Gustavson, Mark D ^a  

^a HistoRx   (United States)

Author keywords

Biomarkers; Cancer; Diagnostics; Image analysis; Immunofluorescence; Immunohistochemistry; Oncology; Personalized medicine; Prognosis; Tissue microarrays

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BIOLOGICAL MARKER; CD20 ANTIGEN; CD99 ANTIGEN; CYTOKERATIN; GLIAL FIBRILLARY ACIDIC PROTEIN; PAN CYTOKERATIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

BREAST CANCER; CANCER PROGNOSIS; COLON CANCER; COMPUTER PROGRAM; DIAGNOSTIC TEST; DISEASE COURSE; GLIOBLASTOMA; HEAD AND NECK CANCER; HEALTH SURVEY; HUMAN; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; OVARY CANCER; PANCREAS CANCER; PREDICTOR VARIABLE; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVIEW; SARCOMA; TISSUE MICROARRAY; URINARY TRACT CANCER; UTERINE CERVIX CANCER;

EID: 84867963815     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.708336     Document Type: Review

References (106)

1. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 1986;55(2):244-8
2. Wan WH, Fortuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 1987;103(1):121-9
3. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4(7):844-7
4. Sauter G. Representativity of TMA studies. Methods Mol Biol 2010;664:27-35.
5. Sauter G, Mirlacher M. Tissue microarrays for predictive molecular pathology. J Clin Pathol 2002;55(8):575-6
6. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008;26(34):5630-7
7. Simon R, Mirlacher M, Sauter G. Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 2010;664:113-26
8. Dolled-Filhart M, Gustavson M, Camp RL, et al. Automated analysis of tissue microarrays. Methods Mol Biol 2010;664:151-62
9. Kallioniemi A. DNA copy number analysis on tissue microarrays. Methods Mol Biol 2010;664:127-34
10. Rummukainen JK, Salminen T, Lundin J, et al. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001;81(11):1545-51
11. Veeck J, Dahl E. RNA expression analysis on formalin-fixed paraffinembedded tissues in TMA format by RNA in situ hybridization. Methods Mol Biol 664:135-50
12. Bordeaux JM, Cheng H, Welsh AW, et al. Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. PLoS One 2012;7(5):e36559
13. Hanna JA, Wimberly H, Kumar S, et al. Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques 2012;52(4):235-45
14. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80(12):1943-9
15. Rubin MA, Dunn R, Strawderman M, et al. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26(3):312-19
16. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003;16(1):79-84
17. Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194(3):349-57
18. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883-92
19. Rimm DL, Nielsen TO, Jewell SD, et al. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol 29(16):2282-90
20. Franco R, Caraglia M, Facchini G, et al. The role of tissue microarray in the era of target-based agents. Expert Rev Anticancer Ther 2011;11(6):859-69
21. Mengel M, von Wasielewski R, Wiese B, et al. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 2002;198(3):292-9
22. De la Taille A, Viellefond A, Berger N, et al. Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays. Hum Pathol 2003;34(5):444-9
23. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002;117(5):723-8
24. Tennstedt P, Sauter G. Quality aspects of TMA analysis. Methods Mol Biol 2010;664:17-26
25. Harigopal M, Barlow WE, Tedeschi G, et al. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 2010;176(4):1639-47
26. Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88(15):1054-9
27. DiVito KA, Charette LA, Rimm DL, et al. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004;84(8):1071-8
28. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998;51(5):370-4
29. Manne U, Myers RB, Srivastava S, et al. Re: loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1997;89(8):585-6
30. Mirlacher M, Kasper M, Storz M, et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 2004;17(11):1414-20
31. Chin SF, Daigo Y, Huang HE, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003;56(5):275-9
32. Andersen CL, Hostetter G, Grigoryan A, et al. Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry 2001;45(2):83-6
33. Pires AR, de Souza SR. Hypodermic needle without recipient paraffin block technique. Methods Mol Biol 2010;664:53-61
34. Gurgel DC, Dornelas CA, Lima-Junior RC, et al. An adapted tissue microarray for the development of a matrix arrangement of tissue samples. Pathol Res Pract 2012;208(3):167-8
35. Tran TH, Lin J, Sjolund AB, et al. Protocol for constructing tissue arrays by cutting edge matrix assembly. Methods Mol Biol 2010;664:45-52
36. Fejzo MS, Slamon DJ. Tissue microarrays from frozen tissues-OCT technique. Methods Mol Biol 2010;664:73-80
37. Hu Z, Chang E, Hodeib M. An alternative technology to prepare tissue microarray using frozen tissue samples. Methods Mol Biol 2010;664:81-91
38. Howat WJ, Wilson SJ. Resin technologies: construction and staining of resin TMA's. Methods Mol Biol 2010;664:63-72
39. Krenacs T, Ficsor L, Varga SV, et al. Digital microscopy for boosting database integration and analysis in TMA studies. Methods Mol Biol 2010;664:163-75
40. Hober S, Uhlen M. Human protein atlas and the use of microarray technologies. Curr Opin Biotechnol 2008;19(1):30-5
41. Cowan JD, Rimm DL, Tuck DP. Cruella: developing a scalable tissue microarray data management system. Arch Pathol Lab Med 2006;130(6):817-22
42. Andersen CL, Monni O, Wagner U, et al. High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol 2002;161(1):73-9
43. Schlomm T, Chun F, Erbersdobler A. From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer. Methods Mol Biol 2010;664:177-89
44. Cantile M, Franco R, Tschan A, et al. HOX D13 expression across 79 tumor tissue types. Int J Cancer 2009;125(7):1532-41
45. Tebcherani AJ, de Andrade HF Jr, Sotto MN. Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples. Mod Pathol 2012. Available from: http://www.ncbi. nlm.nih.gov/pubmed/22684216? dopt=Citation
46. Drev P, Grazio SF, Bracko M. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl Immunohistochem Mol Morphol 2008;16(2):179-84
47. Rossing HH, Talman ML, Laenkholm AV, et al. Implementation of TMA and digitalization in routine diagnostics of breast pathology. APMIS 2012;120(4):341-7
48. Rubin MA, Mucci NR, Figurski J, et al. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 2001;32(7):690-7
49. Harigopal M, Berger AJ, Camp RL, et al. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res 2005;11(11):4083-9
50. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11(18):6598-607
51. Bartlett JM, Brookes CL, Robson T, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 2011;29(12):1531-8
52. Giltnane JM, Ryden L, Cregger M, et al. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 2007;25(21):3007-14
53. Alkner S, Bendahl PO, Grabau D, et al. AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol 2009;21(2):238-44
54. Zhao S, Natkunam Y. Building "tissue" microarrays from suspension cells. Methods Mol Biol 2010;664:93-101
55. Datta MW, Kajdacsy-Balla AA. Tissue microarrays from biopsy specimens. Methods Mol Biol 2010;664:103-11
56. Kellner A, Matschke J, Bernreuther C, et al. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol 2009;65(1):24-31
57. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999;91(20):1758-64
58. Rojo MG, Bueno G, Slodkowska J. Review of imaging solutions for integrated quantitative immunohistochemistry in the pathology daily practice. Folia Histochem Cytobiol 2009;47(3):349-54
59. Mulrane L, Rexhepaj E, Penney S, et al. Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Rev Mol Diagn 2008;8(6):707-25
60. Rojo MG, Garcia GB, Mateos CP, et al. Critical comparison of 31 commercially available digital slide systems in pathology. Int J Surg Pathol 2006;14(4):285-305
61. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8(11):1323-7
62. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21(Suppl 2):S8-S15
63. Welsh AW, Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011;29(22):2978-84
64. Dolled-Filhart M, McCabe A, Giltnane J, et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006;66(10):5487-94
65. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97(24):1808-15
66. Gustavson MD, Bourke-Martin B, Reilly D, et al. Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med 2009;133(9):1413-19
67. Gustavson MD, Bourke-Martin B, Reilly DM, et al. Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using automated QUantitative analysis. Appl Immunohistochem Mol Morphol 2009;17(4):329-37
68. Brocton N, Dort J, Lau H, et al. High stromal carbonic anhydrase IX expression is associated with decreased survival in p16negative head-and-neck tumors. Int J Radiat Oncol Biol Phys 2010;80(1):249-57
69. Berger AJ, Camp RL, DiVito KA, et al. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome 11. Cancer Res 2004;64(23):8767-72
70. Yang DT, Quann PJ, Petrich AM, et al. Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma. Appl Immunohistochem Mol Morphol 2010;19(1):62-9
71. Sullivan CA, Ghosh S, Ocal IT, et al. Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer. Hum Pathol 2009;40(2):156-65
72. Kluger HM, Siddiqui SF, Angeletti C, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest 2008;88(9):962-72
73. Rahrmann EP, Collier LS, Knutson TP, et al. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res 2009;69(10): 4388-97
74. Mertz KD, Demichelis F, Kim R, et al. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 2007;38(10):1454-62
75. Neumeister V, Agarwal S, Bordeaux J, et al. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010;176(5):2131-8
76. Hoyt CC, Gustavson MD, Romeo E, et al. Standardized quantitative methods for investigating the intratumor heterogeneity of HER2 in FFPE breast cancer specimens utilizing the vectra system, inForm and AQUA technology. 2012
77. Baquero MT, Lostritto K, Gustavson MD, et al. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res 2011;13(5):R85
78. Chung GG, Zerkowski MP, Ghosh S, et al. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 2007;87(7):662-9
79. Faratian D, Christiansen J, Gustavson M, et al. Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence. J Vis Exp 2011;(56). Available from: http://www.ncbi.nlm.nih.gov/pubmed/22064683?dopt= Citation
80. Tolles J, Bai Y, Baquero M, et al. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res 2011;13(3):R51
81. Bai Y, Tolles J, Cheng H, et al. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 2011;91(8):1253-61
82. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 2007;25(34):5418-25
83. Pozner-Moulis S, Cregger M, Camp RL, et al. Antibody validation by quantitative analysis of protein expression using expression of met in breast cancer as a model. Lab Invest 2007;87(3):251-60
84. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2011;17(21):7796-807
85. Mascaux C, Wynes MW, Kato Y, et al. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor-a novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res 2011;17(24):7796-807
86. Giltnane JM, Molinaro A, Cheng H, et al. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med 2008;132(10):1635-47
87. Dolled-Filhart M, Ryden L, Cregger M, et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 2006;12(21):6459-68
88. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2010;164(3):831-40
89. Chiappori AA, Zheng Z, Chen T, et al. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol 2010;5(4):484-90
90. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization 9. Clin Cancer Res 2004;10(21):7252-9
91. Emerson JW, Dolled-Filhart M, Harris L, et al. Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation. Cancer Inform 2009;7:29-40
92. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2011;118(6):1607-18
93. Anagnostou VK, Dimou AT, Botsis T, et al. Molecular classification of nonsmall-cell lung cancer using a 4-protein quantitative assay. Cancer 2011;118(6):1607-18
94. Holzer TR, Gustavson M, Pinard R, et al. Development and Analytical Validation of a Quantitative Tissue-Based Assay for Phospho-Smad2 (Ser465/467) in Glioblastoma Multiforme: A Potential Biomarker of TGF-beta Pathway Activation Level. 2011
95. Gould Rothberg BE, Berger AJ, Molinaro AM, et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 2010;27(34):5772-80
96. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010;16(14):3526-32
97. Coughlin CM, Alvarez JD, Edwards R, et al. Src pathway activation identifies subsets of breast cancer patients with predicted resistance to therapy. 2008
98. Camp RL, Dolled-Filhart M, King BL, et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome 31. Cancer Res 2010;63(7):1445-8
99. Doll CM, Prystajecky M, Eliasziw M, et al. Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol 2010;97(2):352-9
100. Gustavson MD, Molinaro AM, Tedeschi G, et al. AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma. Arch Pathol Lab Med 2008;132(11):1746-52
101. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005;11(16): 5856-62
102. Psyrri A, Bamias A, Yu Z, et al. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 2005;11(23):8384-90
103. Akita H, Zheng Z, Takeda Y, et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009;28(32):2903-9
104. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements 23. Am J Pathol 2010;164(3):831-40
105. Bui MM, Zheng Z, Antonia S, et al. Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNET. Fetal Pediatr Pathol 2010;29(6):385-92
106. Harshman LC, Bepler G, Zheng Z, et al. Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int 2010;106(11): 1805-11